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Abstract
Background: T follicular helper (TFH) cells are a special subpopulation of T helper cells and can regulate humoral immune
responses. This study examined whether the frequency of CD4
+CXCR5
+ TFH cells could be associated with active immunity
in chronic hepatitis B (CHB) patients.
Methodology and Findings: The frequencies of peripheral blood CD4
+CXCR5
+ TFH cells, inducible T cell costimulator (ICOS),
and/or programmed death 1 (PD-1) positive CD4
+CXCR5
+ TFH cells in immune-active (IA), immune-tolerant (IT) CHB, and healthy
controls (HC) were characterized by flow cytometry analysis. The effect of adevofir dipivoxil treatment on the frequency of
CD4
+CXCR5
+ TFH cells, the concentrations of serum IL-2, IFN-c, TNF-a,I L - 4 ,I L - 6 ,I L - 1 0 ,I L - 2 1 ,A L T ,A S T ,H B s A g ,H B s A b ,H B e A g ,
HBeAb and HBV loads in IA patients were determined. The potential association of the frequency of CD4
+CXCR5
+ TFH cells with
clinical measures was analyzed. In addition, the frequency of splenic and liver CD4
+CXCR5
+ TFH cells in HBV-transgenic mice was
examined. We found that the frequency of CD4
+CXCR5
+ TFH cells in IA patients was significantly higher than that of IT patients
and HC, and the percentages of CD4
+CXCR5
+ TFH in IA patients were positively correlated with AST. Furthermore, the
percentages of ICOS
+,P D - 1
+, and ICOS
+PD-1
+ in CD4
+CXCR5
+ TFH cells in CHB patients were significantly higher than that of HC.
Treatment with adefovir dipivoxil reduced the frequency of CD4
+CXCR5
+ TFH, PD-1
+CD4
+CXCR5
+ TFH cells and the
concentrations of HBsAg and HBeAg, but increased the concentrations of HBsAb, HBeAb, IL-2 and IFN-c in IA patients. Moreover,
the frequency of splenic and liver CD4
+CXCR5
+ TFH cells in HBV-transgenic mice was higher than that of wild-type controls.
Conclusions: These data indicate that CD4
+CXCR5
+ TFH cells may participate in the HBV-related immune responses and that
high frequency of CD4
+CXCR5
+ TFH cells may be a biomarker for the evaluation of active immune stage of CHB patients.
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Introduction
HBV infection is a global health concern and an economical
burden, affecting approximately 400 million people worldwide [1].
Many patients infected with HBV progress into chronic hepatitis B
(CHB) and can develop end-stage consequences (cirrhosis and
hepatocellular carcinoma) [1]. There are about 130 million
patients with HBV infection and 20% of them develop CHB in
China [1]. During the HBV-infection, the interaction between
replicating noncytopathic virus and dysregulatory host antiviral
immunity determines the outcome [2]. Furthermore, the responses
of individual patients to anti-virus drug treatment are also variable.
Apparently, host and viral factors contribute to variable
biochemical, virological, and histological profiles at different
stages of the process of CHB [2–5]. Previous studies indicate that
dynamic interactions between the virus, hepatocytes, and the host
immune system may determine viral persistence and disease
progression, which are displayed in distinct successive phases [4].
Individuals with HBV infection at immune-tolerant (IT) phase can
display effective replication of HBV, but with no obvious liver
damage and normal levels of serum alanine aminotransferase
(ALT). However, others at immune-active phase (IA) can exhibit
severe liver damage with abnormal levels of ALT, but reduced
numbers of HBV DNA loads [6–8]. These different stages of the
process of CHB may be attributed to host variable immune
responses.
A previous study has suggested that the failure of T cells to
respond to HBV is associated with a persistent HBV replication [9].
T cell-mediated cellularimmunityisinvolvedinboth viralclearance
and liver injury during the HBV-infection [9,10]. Indeed,
conventional treatment of HBV-infected patients can stop or slow
the progression of the disease and reduce complications, but it
cannot reverse liver damage [9]. Hence, understanding the disease
process and immune response is crucial for the establishment of
effective therapies for CHB and reducing liver damage. Currently,
the pathogenesis of virus-related chronic liver disease is not well
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21698understood, and the importance of innate and adaptive immune
responses during the CHB progression is also poorly characterized.
CD4
+ T helper cells are central regulators of immune responses,
and can be classified into different subsets, according to their lineage-
specific transcription factor expression, cytokine production, and
subsequent immune functions [11,12]. Notably, recent studies have
demonstrated that an additional effector subset, follicular helper T
(TFH) cells, is largely responsible for B cell help during an immune
response, and they located in the apex of the light zone in germinal
centers [13,14]. TFH cells express chemokine receptor CXCR5,
which is critical for their functions, and TFH cells also express ICOS,
PD-1, and IL-21, which provide excellent markers for identification
of TFH cells [14,15,16]. ICOS appears to be important for TFH cell
development, and PD-1 is a critical regulator of the function of TFH
cells and IL-21, a cytokine that is critical for the formation of germinal
centers and the development of TFH cells [14,15,16]. Interestingly,
dysregulated TFH cell function has been reported in patients with
lymphoma, such as angioimmunoblastic-T-cell lymphomas (AITL),
and primary cutaneous CD4
+ small/medium-sized pleomorphic T-
cell lymphoma (CSTCL) and autoimmune diseases, such as systemic
lupus erythematosus (SLE) [17,18,19]. However, little is known on
the frequency of TFH cells in CHB patients.
In this study, we explored the frequency of TFH cells in human
peripheral blood from patients with CHB at IA and IT phases,
and examined the potential association of the frequency of TFH
cells with laboratory measures. We found a high frequency of TFH
cells in CHB patients at IA stage, which was positively associated
with the levels of serum AST in this population. We discussed the
implications of our findings.
Result
High frequency of TFH cells in the peripheral blood of IA
patients
To determine T cell immunity, 23 IA and 13 IT patients and 12
healthy subjects were recruited. As shown in Table 1, there was no
significant difference in the distribution of age and gender in this
population. As expected, the levels of serum ALT and AST in IA
patients were significantly higher than that of IT patients and healthy
subjects, while the levels of HBV DNA loads in IA patients were
significantly lower than that of IT patients. To investigate the
potential role of peripheral TFH cells in HBV-infection patients, the
frequency of peripheral blood CD4
+CXCR5
+ in CD4
+ T cells and
the percentages of ICOS
+CD4
+CXCR5
+ and PD-1
+CD4
+CXCR5
+
in TFH cells were analyzed by flow cytometry (Fig. 1). Interestingly,
the percentages of CD4
+CXCR5
+ TFH cells in IA patients were
significantly higher than that in IT patients (P=0.023) and healthy
individuals (P , 0.001, Fig. 2A). Furthermore, the percentages of
ICOS
+CD4
+CXCR5
+,P D - 1
+CD4
+CXCR5
+,a n dI C O S
+PD-
1
+CD4
+CXCR5
+ TFH cells was similar between IA and IT patients,
although they were significantly higher than that of healthy subjects
(P, 0.05, Fig. 2B–D). There was no significant difference in the
concentrations of serum IL-21 between IA and IT patients (data not
shown). Further stratification indicated that there was no significant
difference in the frequency of CD4
+CXCR5
+ TFH cells between IA
patients with positive HBeAg and negative HBeAg (data not shown).
More importantly, Spearman’s correlation analysis revealed that the
frequency of CD4
+CXCR5
+ TFH cells was significantly correlated
with the concentrations of AST (r=0.482, P=0.02, Fig. 3A), but not
with ALT (Fig. 3B) and the levels of HBV DNA loads (Fig. 3C) in IA
patients. Apparently, thehighfrequency ofCD4
+CXCR5
+TFHcells
w a sa s s o c i a t e dw i t hl e v e l so fs e r u mA S Ti nI Ap a t i e n t si nt h i sc h i n e s e
population.
Treatment with Adefovir dipivoxil significantly reduces
the frequency of CD4
+CXCR5
+ TFH cells in IA patients
Those 23 IA patients were treated with adefovir dipivoxil for 12
weeks, and their percentages of CD4
+CXCR5
+ TFH cells were
characterized before and after drug treatment, respectively. There
were 15 IA patients responding to drug, while the other 8 patients
did not (Table 2). Evidentially, following treatment with adefovir
dipivoxil, all patients displayed reduced levels of serum ALT and
AST, but the levels of serum HBV DNA loads only in those drug
response IA patients were reduced significantly, as compared with
that of before treatment. Notably, the frequency of CD4
+CXCR5
+
TFH cells was correlatively positively with the amounts of serum
HBVDNAinthosedrug-respondingpatientsbeforedrug treatment
(R
2=0.3005, P=0.011, Fig. 4C). Further analysis of TFH cells
indicated that, in comparison with that before treatment, the
Table 1. The demographic and clinical characteristics of subjects.
Parameters Immune-active (IA) Immune-tolerant (IT) Healthy controls
NO. 23 13 12
Age (years)
Mean 6 SD 42.968.1 40.866.7 35.75612.35
Median (range) 45 (30–61) 38 (30–58) 35 (23–50)
Sex N (%)
Male 19 (83) 9 (69) 9 (75)
Female 4 (17) 4 (31) 3 (25)
HBV DNA (log10 copies/ml)
Median (range) 4.8* (3.5–6.8) 6.9 (5.2–7.5) NA
ALT (U/L)
Median (range) 135* (46–2343) 30 (17–40) 15 (5–20)
AST (U/L)
Median (range) 104.5* (24–876) 24 (21–39) 11 (9–25)
Normal values: ALT#40 IU/L; AST#40 IU/L; HBV DNA #3 log10 copies/ml;
*P,0.05 vs. IA patients.
doi:10.1371/journal.pone.0021698.t001
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+CXCR5
+ and PD-1
+CD4
+CXCR5
+, but not
ICOS
+CD4
+CXCR5
+ and ICOS
+PD-1
+CD4
+CXCR5
+ THF
cells, was also significantly reduced in drug responded IA patients
(P, 0.05 for both, Fig. 4A, B). In contrast, there was no significant
difference in the frequency of CD4
+CXCR5
+,P D -
1
+CD4
+CXCR5
+, ICOS
+CD4
+CXCR5
+ and ICOS
+PD-
1
+CD4
+CXCR5
+ THF cells in drug non-response IA patients
(data not shown). Clearly, treatment with adefovir dipivoxil
inhibited the replication of HBV and demolished CD4
+CXCR5
+
and PD-1
+CD4
+CXCR5
+ THF cells in IA patients.
Treatment with adefovir dipivoxil modulates serum
cytokines and HBV-related humoral responses in drug
response patients
To further understand the effect of treatment with adefovir
dipivoxil, we detected the concentrations of serum cytokines before
and after drug treatment by cytometric bead array (CBA) and
ELISA. We found that the concentrations of IL-2 and IFN-c, but
not IL-4, IL-6, IL-10, IL-21, and TNF-a, after treatment with
adefovir dipivoxil were significantly higher than that before
treatment in those patients (Fig. 5). However, there was no
significant difference in the concentrations of serum cytokines
tested in those drug non-response patients (data not shown).
Furthermore, the changes in the concentrations of serum cytokines
werenot associated with HBV DNAloads,ALT,andAST(datanot
shown). Apparently, treatment with adefovir dipivoxil modulated
systemic cytokine responses in patients with CHB at IA phase.
Further characterization of serum HBsAg, HBsAb, HBeAg, and
HBeAb revealed that the concentrations of serum HBeAb were
correlated negatively with the frequency of CD4
+CXCR5
+ TFH
cells in patients with CHB at IA phase (r=20.479, P=0.013).
Furthermore, treatment with adefovir dipivoxil slightly reduced
the levels of serum HBsAg but increased HBsAb, but did not reach
a statistically significant difference between before and after drug
treatment (Table 2). In addition, treatment with adefovir dipivoxil
significantly decreased the levels of serum HBeAg, but increased
the levels of serum HBeAb in drug-responding patients, but not in
Figure 2. High frequency of TFH cells in the peripheral blood of IA patients. (A) The percentages of CXCR5
+CD4
+ in the total CD4
+ T cells.
(B) The percentages of ICOS
+CXCR5
+CD4
+ in total CXCR5
+CD4
+ cells. (C) The percentage of PD-1
+CXCR5
+CD4
+ in total CXCR5
+CD4
+ cells. (D) The
percentage of ICOS
+PD-1
+CXCR5
+CD4
+ in total CXCR5
+CD4
+ cells. Data are expressed as mean % of individual samples from at least two separate
experiments. The horizontal lines show the median.
doi:10.1371/journal.pone.0021698.g002
Figure 1. FACS analysis of TFH cells. Peripheral mononuclear cells were stained in duplicate with anti-CD4, anti-ICOS, anti-PD-1 or isotype-
matched IgG, respectively. The cells were gated initially on living lymphocytes (top left) and then on CD4
+ T cells (top right). Subsequently, the
frequency of CXCR5
+CD4
+, ICOS
+CXCR5
+CD4
+, and PD-1
+CXCR5
+CD4
+ cells were analyzed by flow cytometry. At least about 50,000 events were
analyzed for each sample and data are representatives of different groups of samples from at least two independent experiments.
doi:10.1371/journal.pone.0021698.g001
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adefovir dipivoxil modulated systemic cytokine and HBV-related
immune responses.
High frequency of spelnic and liver CD4
+CXCR5
+ TFH
Cells in HBV-transgenic mice
HBV transgenic mice display many characteristics, similar to
that in CHB patients, providing an excellent model for the
evaluation of spontaneous immune response. We further charac-
terized the frequency of splenic and liver CD4
+CXCR5
+ THF
cells in HBV transgenic and wild-type mice. We found that the
frequency of splenic and liver CD4
+CXCR5
+ THF cells in HBV
transgenic mice was significantly higher than those in wild-type
C57BL/6 mice (p , 0.05 for both, Fig. 6). Therefore, the high
frequency of CD4
+CXCR5
+ THF cells may reflect an active status
of CHB patients.
Figure 3. The correlation of the levels of serum AST, ALT, HBV DNA load with CXCR5
+CD4
+ TFH cells in drug-response IA patients.
(A) AST. (B) ALT. (C) HBV DNA load. Data are expressed as mean values of individual patients (n=27) from three separate experiments.
doi:10.1371/journal.pone.0021698.g003
Table 2. Treatment with adefovir dipivoxil modulates the clinical profiles of IA patients.
Group Drug responded (n=15) Drug non-response (n=8)
Before After Before After
ALT (U/L) 125 (46–2343) 42 (23–69)* 130 (112–1138) 68 (39–127)*
AST (U/L) 104.5 (24–787) 39 (23–47)* 89 (48–876) 35 (16–65)*
HBVDNA (log10copies/ml) 6.0 (5.2–7.0) 2.5 (0.3–3.1)* 5.8 (3.7–7.5) 4.9 (2.4–6.7)
HBsAg (IU/ml) 5002.04 (1243.65–55925.04) 3478.45 (890.34–17118.09) 4239.8 (224.59–22160.14) 4965.49 (654.8–18420.66)
HBsAb (mIU/ml) 0.01 (0–3.71) 0.4 (0–4.41) 0 (0–3.2) 0.55(0–3.85)
HBeAg (S/CO) 2189.6 (3.88–4094.10)* 539.62 (0.47–2345.67)* 555.855 (1.311–5573.35) 284.626 (3.24–4167.3)
HBeAb (S/CO) 16.71(0.02–46.74)* 1.26(0.01–35.67)* 32.55 (0.83–44.76) 13.23 (1.16–32.59)
Data are expressed as median (range) or real case numbers.
*P,0.05 vs. before treatment.
doi:10.1371/journal.pone.0021698.t002
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TFH cells are crucial regulators and have been associated with
the pathogenic process of many diseases in humans [17–19]. The
present study characterized the frequency of peripheral TFH cells
in IA and IT CHB patients and HC, and revealed that the
frequency of peripheral blood CD4
+CXCR5
+ TFH cells in IA
patients was significantly higher than that of IT patients and HC.
In addition, treatment with adefovir dipivoxil for 12 weeks
significantly reduced the percentage of CD4
+CXCR5
+ TFH cells
in drug-responding IA patients. Finally, the percentages of splenic
and liver CD4
+CXCR5
+ TFH cells in HBV-transgenic mice were
significantly higher than that of wild-type mice. These findings
clearly indicate that TFH cells participate in the HBV-related
immune responses.
The persistent HBV-infection in CHB patients is usually
associated with quantitative and qualitative exhaustion of
functional T cells [20]. The frequency of peripheral blood TFH
cells in CHB patients varies at different stages of the process of
chronic HBV-infection. Simpson and colleagues found that high
frequency of peripheral blood TFH cells was detected in patients
with active systemic lupus erythematosus (SLE) and Sjogren’s
syndrome (SS) and they also expressed ICOS, CXCR5, and PD-1
[19]. In this study, we found a higher frequency of CD4
+CXCR5
+
TFH cells in IA patients and increased frequency of ICOS-, PD-1-
expressing CD4
+CXCR5
+ in CHB patients. Our data support the
notion that TFH cells can circulate in peripheral blood [21]. The
increased frequency of TFH cells may reflect active immune
responses because TFH cells are crucial for antigen-specific B cell
development and humoral responses against virus infection.
Indeed, TFH cells have been thought to be resting memory TH
cells [21]. However, we found that the frequency of
CD4
+CXCR5
+ TFH cells was correlated negatively with the
concentrations of serum HBeAb in CHB patients and that
treatment with adefovir dipivoxil reduced the frequency of
CD4
+CXCR5
+ TFH cells, but increased the levels of serum
HBeAb, accompanied by increased levels of serum Th1 cytokines
in drug-responding patients. Apparently, high frequency of TFH
cells is associated with a poor immunity against HBV infection.
Alternatively, the increased frequency of peripheral blood TFH
cells may stem from the altered distribution of Th1 and Th2 cells
due to their infiltration in the target organs [22,23]. However, we
found that the percentages of splenic and liver CD4
+CXCR5
+
TFH cells in HBV-transgenic mice were significantly higher than
that of wild-type mice, indicating that CD4
+CXCR5
+ TFH cells
also migrated into the target organ in this model. More
importantly, we found a positive correlation between the
percentages of peripheral blood CD4
+CXCR5
+ TFH cells and
Figure 4. Treatment with adefovir dipivoxil modulates the frequency of TFH cells in IA patients. A total of 23 IA patients were treated
with adefovir dipivoxil for 12 weeks and the frequency of TFH cells in peripheral blood was determined by flow cytometry analysis before and after
treatment. (A) The percentage of CXCR5
+CD4
+ TFH cells in the total CD4
+T cells; (B) The percentage of PD-1
+CXCR5
+CD4
+ cells in total CXCR5
+CD4
+
cells. Data are expressed as mean % of individual patients who were drug responders (n=15). The horizontal lines indicate the median values of
different groups. (C) The correlation of the frequency of CXCR5
+CD4
+ cells with the amount of serum HBV DNA in drug-responding patients before
drug treatment.
doi:10.1371/journal.pone.0021698.g004
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correlation further suggests that TFH cells are associated with the
HBV-related damages in the liver and indicates that the frequency
of TFH cells may be another valuable biomarker (in addition to
AST, ALT and HBV DNA loads) for distinguishing CHB patients
at IA from IT phase. The high frequency of TFH cells may be a
valuable biomarker for the evaluation of immune status in CHB
patients at clinic. Notably, there was no significant correlation of
the frequency of CD4
+CXCR5
+ TFH cells with the levels of
serum ALT in IA patients. This may come from the population
heterogeneity and small sample size in this study.
Adefovir dipivoxil is a potent antiviral reagent, and treatment
with adefovir dipivoxil can effectively inhibit the replication of
HBV in the majority of CHB patients. Our previous studies have
shown that treatment with adefovir dipivoxil enhanced T cell
immunity, which was associated with the inhibition of HBV
replication in CHB patients [22,23]. In this study, we further
examined the impact of treatment with adefovir dipivoxil on
systemic cytokine responses and found that treatment with
adefovir dipivoxil significantly elevated the concentrations of
serum IL-2 and IFN-c, but did not affect the levels of serum IL-4,
IL-6, IL-10, IL-21, and TNF-a in drug-responding patients. These
results suggest that adefovir dipivoxil inhibits HBV DNA
replication and promotes Th1 responses. Interestingly we found
that treatment with adefovir dipivoxil for 12 weeks not only
significantly decreased the concentrations of serum HBsAg,
HBeAg, ALT, AST, and HBV virus loads, but also dramatically
reduced the frequency of TFH cells, particularly for PD-
1
+CD4
+CXCR5
+ TFH cells, in the drug-responding IA patients.
Treatment with adefovir dipivoxil also increased the levels of serum
HBeAb in those patients. However, this treatment only slightly
reduced the values of clinical measures and the frequency of TFH
cells in the drug non-responding IA patients. Engagement of PD-1
by PDL1inactivated T cellsusuallymediates a negativesignalforT
cell function, and the levels of PD-1 expression are negatively
associated with the activities of CD8
+ T cells in CHB patients [20].
The decreased frequency of PD-1
+CD4
+CXCR5
+ by adefovir
dipivoxil treatment may be associated with increased T cell
immunity in CHB patients. Alternatively, the decreased frequency
of PD-1
+CD4
+CXCR5
+ TFH cells may come from dramatically
Figure 5. Analysis of serum cytokines in drug-response IA patients. The concentrations of serum TH1/TH2 (A), TFH (B) cytokines in drug-
response IA patients before (black circle) and after (black square) adefovir dipivoxil treatment were examined by CBA. Data are expressed as mean
values of individual patients (n=15) from two separate experiments. The horizontal lines indicate the median values of different groups.
doi:10.1371/journal.pone.0021698.g005
Figure 6. High frequency of TFH cells in the livers and spleens of HBV transgenic mice. HBV transgenic (n=7) and wild-type (n=6) of
C57BL/6 mice at eight weeks of age were sacrificed, and their liver and splenic mononuclear cells were prepared. The frequency of splenic and liver
CD4
+CXCR5
+ T cells was determined by flow cytometry analysis. (A) The percentage of splenic TFH cells. (B) The percentage of liver TFH cells. Data are
expressed as mean % of individual mice from each group, and the horizontal lines indicate the median values of each group of mice.
doi:10.1371/journal.pone.0021698.g006
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CD4
+CXCR5
+TFH cells was correlated positively with the levels
of HBV DNA loads in drug-responding IA patients, but negatively
with the concentrations of serum HBeAb in CHB patients.
Treatment with adefovir dipivoxil reduced the frequency of
CD4
+CXCR5
+ TFH cells, but increased the levels of serum
HBeAb in drug-response IA patients. Our data are consistent with
previous findings that the frequency of CD4
+CXCR5
+ TFH cells is
associated negatively with the frequency of plasma cells [13]. The
precise relationship between the frequency of peripheral blood
CD4
+CXCR5
+ TFH cells and the reduced HBV loads, enhanced
frequency of other T cells, and the increased of antibody after
adefovir dipivoxil treatment remains to be further investigated.
In summary, our data indicated that there was a higher
frequency of ICOS- and PD-1-expressing CD4
+CXCR5
+ TFH
cells in CHB patients and that the frequency of peripheral blood
CD4
+CXCR5
+ TFH cells in IA patients was significantly higher
than that of IT patients. More importantly, the percentages of
TFH cells were positively associated with the concentrations of
serum AST in IA patients. These novel findings suggest that TFH
cells participate in the HBV-related immune responses and that
high frequency of TFH cells may be a valuable prognostic
biomarker for the evaluation of immune statuses of CHB patients.
We recognized that this study had limitations of small sample size
and the lack of functional study of TFH cells in the pathogenic
process of CHB and the HBV-related immunity. Therefore,
further study of the function of TFH cells in the pathogenic
process and HBV-related immunity with a bigger population is
warranted.
Materials and Methods
Patients
A total of 36 patients with HBV infection were recruited in the
inpatient service and another 12 healthy subjects were from the
outpatient service of the First Hospital of Jilin University from Mar
2009 to Dec 2010. Individual subjects with HBV infection were
confirmed positive for HBsAg and detectable HBV virions for at
least 12 months [24]. Subjects with positive hepatitis C and D,
HIV infection, with autoimmune hepatitis or metabolic liver
disease, receiving immunosuppressive therapy, or antiviral therapy
within the past 12 months before entry were excluded [24]. All of
the patients denied to being drug users, or having been exposed to
hepatotoxin [24]. Those HBV infected subjects were further
classified into two distinct groups, according to the levels of serum
HBV DNA loads and ALT. Subjects with high copies of serum
HBV DNA loads and normal levels of ALT (normal range: #40
U/L) were considered as IT, but those with relatively low levels of
serum HBV DNA loads and abnormal levels of ALT were defined
as IA, as described previously [6–8,25]. Their demographic and
clinical characteristics are summarized in Table 1.
Those IA patients were treated orally with 10 mg of adefovir
dipivoxil (Gilead Science, Forster City, USA) daily for 12 weeks.
Their serum ALT, AST, HBsAg, HBsAb, HBeAg, HBeAb
concentrations, and HBV DNA loads were analyzed (Table 2).
Individual IA patients with at least 100-fold reduced serum HBV
viral loads were defined as drug response patients, but others were
defined as drug non-response patients. The study conformed for
the guidelines of the Declaration of Helsinki and was approved by
Human Ethics Committee of Jilin University,ChangChun,China.
Written informed consent was obtained from each participant.
Peripheral blood samples were obtained from individual subjects,
and the levels of serum AST and ALT were detected by
Biochemistry Automatic Analyzer (Roche Diagnostics,Branchburg,
USA) [22]. The levels of serum HBV DNA loads were measured by
quantitative PCR assay using the luciferase quantization detection
kit with a detection limit of 300 copies/mL (Roche Amplicor, Basel,
Switzerland), according to the manufacturers’ instruction [22]. The
levels of HBV-related HBsAg, HBsAb, HBeAg, and HBeAb were
determined by a chemiluminescent microparticle immunoassay
(CMIA) using an Abbott I 2000 automated chemiluminescence
immunoassay analyzer (Abbott Laboratories, Abbott Park, Illinois,
USA). The concentrations of serum HBeAb in individual samples
were determined semi-quantitatively by a competitive inhibition
method, according to the manufacturers’ instruction and a previous
report [26]. The data are expressed as median (range) of signal OD
to cut-off (S/CO). Accordingly, the higher concentrations of serum
HBeAb, the lower values of S/CO.
Mice
Both female and male C57BL/6 HBV-transgenic mice and
non-transgenic C57BL/6 mice at 8 weeks of age were purchased
from Vital River Laboratories (Beijing, China). This HBV-
transgenic line of mice displays high levels of serum HBV
replicative DNA, with the log value of the HBV DNA load [5.94,
(5.45–6.40)], and all forms of HBsAg particles, which mimics the
pathogenic process in human patients with CHB [27]. All mice
were housed in a specific pathogen-free facility. The animal
experiment was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Research and Protection
Committee of Jilin University, Changchun, China (SYXK-2010-
0008). The mice were sacrificed, and their livers and spleens were
dissected out. The hepatic mononuclear cells (HMNCs) were
prepared by meshing and Percoll gradient centrifuging. Briefly, the
liver tissue samples were meshed through a 200-gauge stainless
steel filter, and after being washed, the liver cells were centrifuged
and re-suspended in 40% Percoll (Pharmacia, Uppsala, Switzer-
land). Subsequently, the cell suspension was overlaid gently on the
top of 70% Percoll and centrifuged at 2,400 rpm for 30 min at
room temperature [28]. HMNCs were obtained from the
interphase and washed twice with PBS. The remaining erythro-
cytes were removed using lysis solution (Beckton Dickinson, San
Jose, USA).
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated by
density-gradient centrifugation using Ficoll-Paque Plus (Amersham
Biosciences, Little Chalfont, UK). Human PBMCs at 10
6/tube
were stained in duplicate with PerCP-anti-CXCR5 (Biolegend, San
Diego, USA) and APC-anti-CD4, PE-anti-CD278, FITC-anti-
CD279, or isotype-matched control IgG (Beckton Dickinson, San
Jose, USA) at room temperature for 30 minutes, respectively. After
being washed with PBS, the cells were subjected to flow cytometry
analysis using a FACSCalibur (Beckton Dickinson) and FlowJo
software (v5.7.2) [22]. The cells were gated on the forward scatter of
living cells and then centered on CD4
+ T cells. Subsequently, the
CD4
+CXCR5
+, ICOS
+CD4
+CXCR5
+,P D - 1
+CD4
+CXCR5
+,
and ICOS
+PD-1
+CD4
+CXCR5
+ TFH cells were determined by
flow cytometric analysis, and at least 50,000 events per sample were
analyzed.
Additional flow cytometry analysis was performed for mouse
splenic and hepatic mononuclear cells. Briefly, splenic or hepatic
mononuclear cells at 10
7/tube were stained in duplicate with
FITC-anti-CD4 (eBioscience, San Diego, USA) and PE-anti-
CXCR5 (BD Pharmingen, San Diego, USA), and the frequency of
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+CXCR5
+ TFH cells was determined by flow cytometry
analysis.
Enzyme-linked ImmunoSorbent assay (ELISA)
The concentrations of serum IL-21 in individual patients and
HC were determined by ELISA using human IL-21 ELISA Kit,
according to the manufacturers’ instruction (Roche Diagnostics,
Lewes, UK). Individual sera at 1:4 dilutions were subjected to
ELISA analysis, and the concentrations of serum IL-21 in
individual samples were calculated, according to the standard
curve.
Cytometric bead array (CBA) analysis of serum cytokines
The concentrations of serum cytokines were determined by
CBA [29,30], according to the manufacture’s protocol (CBATM,
BD Biosciences, San Joes, USA). The concentrations of cytokines
in individual samples were quantified in duplicate using the CBA
kit on a FACSCalibur cytometry (BD Biosciences) equipped with
CellQuestPro and CBA software (Becton Dickinson).
Statistical analysis
Data are expressed as median and range unless specified. The
difference between two groups was analyzed by Wilcoxon rank
sum test and Chi-square test using the SAS version 8.0 software.
The relationship between two variables was evaluated using the
Spearman rank correlation test. A two-side P value , 0.05 was
considered statistically significant.
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